The OPEN MINDS Executive Blueprint for Crisis ManagementBuilding Organizational Sustainability & Success in a Disrupted Health & Human Service Market
A 32-week program designed to help executive teams navigate the business, organizational, operational, and culture changes of a market in turbulence. The program, based on the seven-component OPEN MINDS executive blueprint, combines a series of 35 live educational web briefings with online technical assistance and a suite of on-demand resources.
PEAR Therapeutics & Novartis Collaborate On Digital Therapeutic For Schizophrenia
On March 1, 2018, PEAR Therapeutics announced a collaboration with Novartis to pursue marketing approval for PEAR's existing THRIVE digital therapeutic focused on schizophrenia. The THRIVE application is intended for use in conjunction with antipsychotic medications. The application provides real-time consumer monitoring and support, and real-time interventions targeting positive symptoms of schizophrenia including hallucinations and delusions. The announcement mentioned no target approval date.
Novartis will provide PEAR with research funding to develop THRIVE and a new therapeutic application for people with multiple sclerosis. The terms also include an upfront payment, milestones, and royalties on net sales. Novartis . . .